Innovative Treatment in Menopause: Tissue-Selective Estrogen Complex (TSEC)
Baquedano L, Sanchez Borrego R, Abad P, Jurado AR, Manubens M and Mendoza N
Article Type: Review Article | First Published: June 30, 2018
Menopause is not a disease, therefore it is not always necessary to treat women in the transition and in menopause. However, hormonal changes can be associated with symptoms, the most common are hot flashes and night sweats. Others like dyspareunia, vaginal dryness, mood swings and sexual disfunction can frequently appear. In addition, there is an increase in bone resorption on ocassions leading to osteopenia and osteoporosis. Women who are severely symptomatic, 25-30% more or less of all menopa...
Hyperhomocysteinemia and Polycystic Ovary Syndrome
Mohamed Nabih EL-Gharib
Article Type: Short Communication | First Published: June 25, 2018
Homocysteine (Hcy) is an essential amino acid required for the growth of cells and tissues. Homocysteine (Hcy) is an intermediate product formed by the breakdown of methionine the aid of certain B-vitamins. Homocysteine remethylation to methionine is dependant on both folate and cobalamin (Figure 1) and may undergo transsulfuration to cysteine and cystathionine....
Does Luteal Phase Deficiency Exist and What is its Association with Infertility?
Monica S Chung, Laurice Bou Nemer and Bruce R Carr
Article Type: Mini Review | First Published: June 06, 2018
Luteal Phase Deficiency (LPD), also known as luteal phase defect, is a concept that was defined by Georgeanna Seegar Jones in 1949 as reduced progesterone production by the Corpus Luteum (CL). LPD results from low endogenous progesterone production and the resultant insufficiency to maintain a secretory endometrium to allow embryo implantation and growth....
Inadvertent Use of Depot GnRH-agonist Trigger and its Effect on the Luteal Phase: A Case Report
Shahar Kol and Ofer Fainaru
Article Type: Case Report | First Published: May 30, 2018
The use of short acting GnRH agonist to trigger final oocyte maturation in IVF is a common practice. Its primary advantage is prevention of significant ovarian hyperstimulation syndrome. The effect of a long acting GnRH agonist preparation in that setting is not known. In the current case report, a depot preparation was given accidentally, resulting in prolonged and robust luteal phase activity, with luteolysis achieved only 14 days after administration....